Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer

被引：0

作者：

Paolo Peterlongo

Gisella Figlioli

Andrew J. Deans

Fergus J. Couch

机构：

[1] IFOM – The FIRC Institute for Molecular Oncology,Genome Diagnostics Program

[2] St Vincent’s Institute,Genome Stability Unit

[3] Fitzroy,Departments of Health Sciences Research

[4] Laboratory Medicine and Pathology,undefined

[5] and Oncology,undefined

[6] Mayo Clinic,undefined

来源：

npj Breast Cancer | / 7卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

FANCM protein truncating variants (PTVs) are emerging as risk factors for ER-negative and triple negative breast cancer. Here, we discuss evidence that greatest risk associates with PTVs, such as p.Arg658*, that extensively truncate the 2048 amino acid FANCM protein. Moreover, risks associated with other less-truncating FANCM PTVs such as p.Gln1701* and p.Gly1906Alafs12* may be amplified by additional gene variants acting as modifiers. Further studies need to be conducted taking into considerations these aspects.

引用

共 50 条

[21] Targeting the mTOR pathway for the prevention of er-negative breast cancer
Mazumdar, Abhijit
Hill, Jamal
Tahaney, William
Ma, Yanxia
Contreras, Alejandro
Sei, Shizuko
Mohammed, Altaf
Brown, Powel
[J]. CANCER RESEARCH, 2022, 82 (12)
[22] Targeting the mTOR pathway for the prevention of ER-negative breast cancer
Mazumdar, Abhijit
Zhang, Yun
Hill, Jamal
Brown, Powel
[J]. CANCER RESEARCH, 2016, 76
[23] Reversal of the ER-negative phenotype in breast cancer by inhibition of MAPK
Brinkman, Joeli
El-Ashry, Dorraya
[J]. CANCER RESEARCH, 2009, 69
[24] Targeting estrogen to kill ER-positive and ER-negative breast cancer
Jordan, VC
[J]. BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S4 - S4
[25] Targeting estrogen to kill ER-positive and ER-negative breast cancer
VC Jordan
[J]. Breast Cancer Research, 7
[26] Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer
Kabisch, Maria
Bermejo, Justo Lorenzo
Duennebier, Thomas
Ying, Shibo
Michailidou, Kyriaki
Bolla, Manjeet K.
Wang, Qin
Dennis, Joe
Shah, Mitul
Perkins, Barbara J.
Czene, Kamila
Darabi, Hatef
Eriksson, Mikael
Bojesen, Stig E.
Nordestgaard, Borge G.
Nielsen, Sune F.
Flyger, Henrik
Lambrechts, Diether
Neven, Patrick
Peeters, Stephanie
Weltens, Caroline
Couch, Fergus J.
Olson, Janet E.
Wang, Xianshu
Purrington, Kristen
Chang-Claude, Jenny
Rudolph, Anja
Seibold, Petra
Flesch-Janys, Dieter
Peto, Julian
dos-Santos-Silva, Isabel
Johnson, Nichola
Fletcher, Olivia
Nevanlinna, Heli
Muranen, Taru A.
Aittomaki, Kristiina
Blomqvist, Carl
Schmidt, Marjanka K.
Broeks, Annegien
Cornelissen, Sten
Hogervorst, Frans B. L.
Li, Jingmei
Brand, Judith S.
Humphreys, Keith
Guenel, Pascal
Truong, Therese
Menegaux, Florence
Sanchez, Marie
Burwinkel, Barbara
Marme, Frederik
[J]. CARCINOGENESIS, 2015, 36 (02) : 256 - 271
[27] ER-Negative Breast Cancer Is Highly Responsive to Cholesterol Metabolite Signalling
Hutchinson, Samantha A.
Lianto, Priscilia
Roberg-Larsen, Hanne
Battaglia, Sebastiano
Hughes, Thomas A.
Thorne, James L.
[J]. NUTRIENTS, 2019, 11 (11)
[28] Prevention of ER-negative breast cancer: where do we stand?
Cazzaniga, Massimiliano
Bonanni, Bernardo
[J]. EUROPEAN JOURNAL OF CANCER PREVENTION, 2012, 21 (02) : 171 - 181
[29] Estradiol increases ER-negative breast cancer metastasis in an experimental model
Xujuan Yang
Aashvini Belosay
Mengyuan Du
Timothy M. Fan
Russell T. Turner
Urszula T. Iwaniec
William G. Helferich
[J]. Clinical & Experimental Metastasis, 2013, 30 : 711 - 721
[30] Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer
Einefors, Rickard
Kogler, Ulrika
Ellberg, Carolina
Olsson, Hakan
[J]. SPRINGERPLUS, 2013, 2 : 1 - 10

← 1 2 3 4 5 →